Max F.
- Country
- Sweden
- Department
- Dept. Of Medicine, Haematology Department
Research Overview
- Evaluation of Intermittent Ibrutinib Administration in Patients with Chronic Lymphocytic Leukemia
- Persistence of Remission Following Discontinuation of BCMA-CD3 Bispecific Antibodies in Multiple Myeloma Patients With Major M-Spike Response
- Phase 3 Randomized Trial of Teclistamab Plus Daratumumab SC vs. Daratumumab SC with Pomalidomide and Dexamethasone or Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 159 of 329 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in multiple myeloma treatment, with particular focus on both newly diagnosed and relapsed/refractory cases. Their research encompasses innovative therapeutic approaches using novel agents and combinations.
- Novel Bispecific Antibodies
- Immunotherapy Combinations
- Post-Transplant Maintenance
The research explores various treatment strategies incorporating monoclonal antibodies and targeted therapies for multiple myeloma patients.
Lymphoid Malignancies
The investigator conducts research in chronic lymphocytic leukemia and small lymphocytic lymphoma, focusing on novel therapeutic approaches and treatment optimization.
- Fixed-Duration Therapies
- MRD-Guided Treatment
- Targeted Therapy Combinations
Their work includes evaluation of venetoclax-based regimens and innovative treatment duration strategies.
Acute Myeloid Leukemia
The investigator studies treatment approaches for newly diagnosed acute myeloid leukemia, with emphasis on enhancing standard therapeutic protocols.
- Enhanced Chemotherapy Protocols
- Minimal Residual Disease Assessment
- Novel Drug Combinations
Research focuses on improving outcomes through combination therapy strategies and treatment optimization.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.